Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studies.

Boof ML, Alatrach A, Ufer M, Dingemanse J.

Eur J Clin Pharmacol. 2018 Oct 4. doi: 10.1007/s00228-018-2559-5. [Epub ahead of print]

PMID:
30284597
2.

The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease.

Neumann U, Ufer M, Jacobson LH, Rouzade-Dominguez ML, Huledal G, Kolly C, Lüönd RM, Machauer R, Veenstra SJ, Hurth K, Rueeger H, Tintelnot-Blomley M, Staufenbiel M, Shimshek DR, Perrot L, Frieauff W, Dubost V, Schiller H, Vogg B, Beltz K, Avrameas A, Kretz S, Pezous N, Rondeau JM, Beckmann N, Hartmann A, Vormfelde S, David OJ, Galli B, Ramos R, Graf A, Lopez Lopez C.

EMBO Mol Med. 2018 Sep 17. pii: e9316. doi: 10.15252/emmm.201809316. [Epub ahead of print]

3.

Clinical Pharmacology of the Reversible and Potent P2Y12 Receptor Antagonist ACT-246475 After Single Subcutaneous Administration in Healthy Male Subjects.

Juif PE, Boehler M, Dobrow M, Ufer M, Dingemanse J.

J Clin Pharmacol. 2018 Aug 8. doi: 10.1002/jcph.1296. [Epub ahead of print]

PMID:
30088663
4.

Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects.

Gardin A, Ufer M, Legangneux E, Rossato G, Jin Y, Su Z, Pal P, Li W, Shakeri-Nejad K.

Clin Pharmacokinet. 2018 Aug 7. doi: 10.1007/s40262-018-0700-3. [Epub ahead of print]

PMID:
30088221
5.

In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics.

Jin Y, Borell H, Gardin A, Ufer M, Huth F, Camenisch G.

Eur J Clin Pharmacol. 2018 Apr;74(4):455-464. doi: 10.1007/s00228-017-2404-2. Epub 2017 Dec 22.

6.

Impact of siponimod on vaccination response in a randomized, placebo-controlled study.

Ufer M, Shakeri-Nejad K, Gardin A, Su Z, Paule I, Marbury TC, Legangneux E.

Neurol Neuroimmunol Neuroinflamm. 2017 Sep 13;4(6):e398. doi: 10.1212/NXI.0000000000000398. eCollection 2017 Nov.

7.

Metabolite profiling in early clinical drug development: current status and future prospects.

Ufer M, Juif PE, Boof ML, Muehlan C, Dingemanse J.

Expert Opin Drug Metab Toxicol. 2017 Aug;13(8):803-806. doi: 10.1080/17425255.2017.1351944. Epub 2017 Jul 13. No abstract available.

PMID:
28689432
8.

The selective metabotropic glutamate receptor 5 antagonist mavoglurant (AFQ056) reduces the incidence of reflux episodes in dogs and patients with moderate to severe gastroesophageal reflux disease.

Rouzade-Dominguez ML, Pezous N, David OJ, Tutuian R, Bruley des Varannes S, Tack J, Malfertheiner P, Allescher HD, Ufer M, Rühl A.

Neurogastroenterol Motil. 2017 Aug;29(8). doi: 10.1111/nmo.13058. Epub 2017 Mar 23.

PMID:
28337838
9.

Intravenous Dosing as an Alternate Approach to Safely Achieve Supratherapeutic Exposure for Assessments of Cardiac Repolarization: A Randomized Clinical Trial with Mavoglurant (AFQ056).

Ufer M, Sagkriotis A, Salunke A, Ganesan S, Tisserant A, Dodman A, Voltz E, Woessner R, Jordaan P, Legangneux E.

Clin Ther. 2016 Dec;38(12):2589-2597. doi: 10.1016/j.clinthera.2016.10.007. Epub 2016 Nov 4.

PMID:
27823869
10.

Effect of mavoglurant (AFQ056), a selective mGluR5 antagonist, on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women.

Sivasubramanian R, Chakraborty A, Rouzade-Dominguez ML, Neelakantham S, Jakab A, Mensinga T, Legangneux E, Woessner R, Ufer M.

Int J Clin Pharmacol Ther. 2015 Jul;53(7):550-6. doi: 10.5414/CP202321.

PMID:
25943176
11.

Development of mavoglurant and its potential for the treatment of fragile X syndrome.

Gomez-Mancilla B, Berry-Kravis E, Hagerman R, von Raison F, Apostol G, Ufer M, Gasparini F, Jacquemont S.

Expert Opin Investig Drugs. 2014 Jan;23(1):125-34. doi: 10.1517/13543784.2014.857400. Epub 2013 Nov 20. Review.

PMID:
24251408
12.

The challenges of clinical trials in fragile X syndrome.

Jacquemont S, Berry-Kravis E, Hagerman R, von Raison F, Gasparini F, Apostol G, Ufer M, Des Portes V, Gomez-Mancilla B.

Psychopharmacology (Berl). 2014 Mar;231(6):1237-50. doi: 10.1007/s00213-013-3289-0. Epub 2013 Oct 31. Review.

13.

Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects.

Walles M, Wolf T, Jin Y, Ritzau M, Leuthold LA, Krauser J, Gschwind HP, Carcache D, Kittelmann M, Ocwieja M, Ufer M, Woessner R, Chakraborty A, Swart P.

Drug Metab Dispos. 2013 Sep;41(9):1626-41. doi: 10.1124/dmd.112.050716. Epub 2013 Jun 17.

14.

Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.

Afsar NA, Ufer M, Haenisch S, Remmler C, Mateen A, Usman A, Ahmed KZ, Ahmad HR, Cascorbi I.

Eur J Clin Pharmacol. 2012 Apr;68(4):389-95. doi: 10.1007/s00228-011-1134-0. Epub 2011 Oct 20.

PMID:
22012257
15.

Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy.

Ufer M, von Stülpnagel C, Muhle H, Haenisch S, Remmler C, Majed A, Plischke H, Stephani U, Kluger G, Cascorbi I.

Pharmacogenet Genomics. 2011 Oct;21(10):624-30. doi: 10.1097/FPC.0b013e3283498131.

PMID:
21799461
16.

Genetic variation in the CYP2C monooxygenase enzyme subfamily shows no association with longevity in a German population.

Flachsbart F, Ufer M, Kleindorp R, Nikolaus S, Schreiber S, Nebel A.

J Gerontol A Biol Sci Med Sci. 2011 Nov;66(11):1186-91. doi: 10.1093/gerona/glr117. Epub 2011 Jul 27.

PMID:
21798861
17.

Caring for caregivers. "Selecting optimal station finishes and furnishings".

Ufer M, Gover M.

Health Facil Manage. 2010 Jun;23(6):27-30. No abstract available.

PMID:
21513246
18.

Transient receptor potential channel polymorphisms are associated with the somatosensory function in neuropathic pain patients.

Binder A, May D, Baron R, Maier C, Tölle TR, Treede RD, Berthele A, Faltraco F, Flor H, Gierthmühlen J, Haenisch S, Huge V, Magerl W, Maihöfner C, Richter H, Rolke R, Scherens A, Uçeyler N, Ufer M, Wasner G, Zhu J, Cascorbi I.

PLoS One. 2011 Mar 29;6(3):e17387. doi: 10.1371/journal.pone.0017387.

19.

Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults.

Muszkat M, Bialer O, Blotnick S, Adar L, Xie HG, Ufer M, Cascorbi I, Caraco Y.

Clin Ther. 2010 Feb;32(2):347-56. doi: 10.1016/j.clinthera.2010.02.008.

PMID:
20206792
20.

Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.

Ufer M.

Thromb Haemost. 2010 Mar;103(3):572-85. doi: 10.1160/TH09-09-0659. Epub 2010 Feb 2. Review.

PMID:
20135071
21.

Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy.

Afsar NA, Haenisch S, Mateen A, Usman A, Ufer M, Ahmed KZ, Ahmad HR, Cascorbi I.

Basic Clin Pharmacol Toxicol. 2010 Jul;107(1):570-6. doi: 10.1111/j.1742-7843.2009.00531.x. Epub 2010 Jan 19.

22.

Quantification of cortisol and 6 beta-hydroxycortisol in human urine by LC-MS/MS, and gender-specific evaluation of the metabolic ratio as biomarker of CYP3A activity.

Lutz U, Bittner N, Ufer M, Lutz WK.

J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Jan 1;878(1):97-101. doi: 10.1016/j.jchromb.2009.11.023.

PMID:
19959402
23.

Decreased sigmoidal ABCB1 (P-glycoprotein) expression in ulcerative colitis is associated with disease activity.

Ufer M, Häsler R, Jacobs G, Haenisch S, Lächelt S, Faltraco F, Sina C, Rosenstiel P, Nikolaus S, Schreiber S, Cascorbi I.

Pharmacogenomics. 2009 Dec;10(12):1941-53. doi: 10.2217/pgs.09.128.

PMID:
19958093
24.

Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C>T polymorphism in young and adult patients with epilepsy.

Ufer M, Mosyagin I, Muhle H, Jacobsen T, Haenisch S, Häsler R, Faltraco F, Remmler C, von Spiczak S, Kroemer HK, Runge U, Boor R, Stephani U, Cascorbi I.

Pharmacogenet Genomics. 2009 May;19(5):353-62.

PMID:
19415824
25.

Major increase of quetiapine steady-state plasma concentration following co-administration of clarithromycin: confirmation of the pharmacokinetic interaction potential of quetiapine.

Schulz-Du Bois C, Schulz-Du Bois AC, Bewig B, Gerstner I, Aldenhoff JB, Cascorbi I, Ufer M.

Pharmacopsychiatry. 2008 Nov;41(6):258-9. doi: 10.1055/s-0028-1082071. Epub 2008 Dec 9. No abstract available.

PMID:
19067264
26.

Additive interaction of the cannabinoid receptor I agonist arachidonyl-2-chloroethylamide with etomidate in a sedation model in mice.

Meybohm P, Brand PA, Ufer M, Thiemann F, Steinfath M, Paris A, Scholz J, Bein B.

Anesthesiology. 2008 Apr;108(4):669-74. doi: 10.1097/ALN.0b013e318167aef7.

PMID:
18362599
27.

Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression.

Ufer M, Dilger K, Leschhorn L, Daufresne L, Mosyagin I, Rosenstiel P, Haesler R, Kuehbacher T, Nikolaus S, Schreiber S, Cascorbi I.

Clin Pharmacol Ther. 2008 Jul;84(1):43-6. doi: 10.1038/sj.clpt.6100505. Epub 2008 Mar 5.

PMID:
18322448
28.

Patterns and prevalence of antidepressant drug use in the German state of Baden-Wuerttemberg: a prescription-based analysis.

Ufer M, Meyer SA, Junge O, Selke G, Volz HP, Hedderich J, Gleiter CH.

Pharmacoepidemiol Drug Saf. 2007 Oct;16(10):1153-60.

PMID:
17443868
29.

Risk of coronary artery disease as influenced by variants of the human endothelin and endothelin-converting enzyme genes.

Bühler K, Ufer M, Müller-Marbach A, Brinkmann U, Laule M, Stangl V, Roots I, Stangl K, Cascorbi I.

Pharmacogenet Genomics. 2007 Jan;17(1):77-83.

PMID:
17264805
30.

CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients.

Renders L, Frisman M, Ufer M, Mosyagin I, Haenisch S, Ott U, Caliebe A, Dechant M, Braun F, Kunzendorf U, Cascorbi I.

Clin Pharmacol Ther. 2007 Feb;81(2):228-34. Epub 2006 Dec 27.

PMID:
17192769
31.

No benefit of 3,4-diaminopyridine in essential tremor: a placebo-controlled crossover study.

Lorenz D, Hagen K, Ufer M, Cascorbi I, Deuschl G, Volkmann J.

Neurology. 2006 Jun 13;66(11):1753-5.

PMID:
16769957
32.
33.

Stereospecific pharmacokinetic characterisation of phenprocoumon metabolites, and mass-spectrometric identification of two novel metabolites in human plasma and liver microsomes.

Kammerer B, Kahlich R, Ufer M, Schenkel A, Laufer S, Gleiter CH.

Anal Bioanal Chem. 2005 Nov;383(6):909-17. Epub 2005 Nov 9.

PMID:
16237546
34.

Paediatric adverse drug reactions reported in Sweden from 1987 to 2001.

Kimland E, Rane A, Ufer M, Panagiotidis G.

Pharmacoepidemiol Drug Saf. 2005 Jul;14(7):493-9.

PMID:
15918163
35.

Effects of CYP2C9 polymorphisms on phenprocoumon anticoagulation status.

Ufer M.

Clin Pharmacol Ther. 2005 Apr;77(4):335-6; author reply 336. No abstract available.

PMID:
15903131
36.

Antimicrobial drug use in hospitalised paediatric patients: a cross-national comparison between Germany and Croatia.

Ufer M, Radosević N, Vogt A, Palcevski G, Francetić I, Reinalter SC, Seyberth HW, Vlahović-Palcevski V.

Pharmacoepidemiol Drug Saf. 2005 Oct;14(10):735-9.

PMID:
15880392
37.

Achiral-chiral LC/LC-MS/MS coupling for determination of chiral discrimination effects in phenprocoumon metabolism.

Kammerer B, Kahlich R, Ufer M, Laufer S, Gleiter CH.

Anal Biochem. 2005 Apr 15;339(2):297-309.

PMID:
15797571
38.

Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo.

Ufer M, Kammerer B, Kahlich R, Kirchheiner J, Yasar U, Brockmöller J, Rane A.

Xenobiotica. 2004 Sep;34(9):847-59.

PMID:
15742978
39.

Determination of phenprocoumon, warfarin and their monohydroxylated metabolites in human plasma and urine by liquid chromatography-mass spectrometry after solid-phase extraction.

Ufer M, Kammerer B, Kirchheiner J, Rane A, Svensson JO.

J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Oct 5;809(2):217-26.

PMID:
15315768
40.

Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers.

Kirchheiner J, Ufer M, Walter EC, Kammerer B, Kahlich R, Meisel C, Schwab M, Gleiter CH, Rane A, Roots I, Brockmöller J.

Pharmacogenetics. 2004 Jan;14(1):19-26.

PMID:
15128047
41.
42.

Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro.

Ufer M, Svensson JO, Krausz KW, Gelboin HV, Rane A, Tybring G.

Eur J Clin Pharmacol. 2004 May;60(3):173-82. Epub 2004 Mar 31.

PMID:
15054565
43.

Determination of (R)- and (S)-phenprocoumon in human plasma by enantioselective liquid chromatography/electrospray ionisation tandem mass spectrometry.

Kammerer B, Kahlich R, Ufer M, Laufer S, Gleiter CH.

Rapid Commun Mass Spectrom. 2004;18(4):458-64.

PMID:
14966853
44.

[Legal issues in unconscious emergency patients].

Ufer MR.

Zentralbl Chir. 2003 Jun;128(6):534-6. German.

PMID:
12865961
45.

Widespread off-label prescribing of topical but not systemic drugs for 350,000 paediatric outpatients in Stockholm.

Ufer M, Rane A, Karlsson A, Kimland E, Bergman U.

Eur J Clin Pharmacol. 2003 Mar;58(11):779-83. Epub 2003 Feb 22.

PMID:
12634986
46.

Amantadine, a N-methyl-D-aspartate receptor antagonist, does not enhance postoperative analgesia in women undergoing abdominal hysterectomy.

Gottschalk A, Schroeder F, Ufer M, Oncü A, Buerkle H, Standl T.

Anesth Analg. 2001 Jul;93(1):192-6.

PMID:
11429364
48.

[Limitations of preclinical emergency medicine from the legal viewpoint].

Ufer MR.

Anasthesiol Intensivmed Notfallmed Schmerzther. 1999 Jan;34(1):3-9. Review. German.

PMID:
10073249
49.

[Hospital "full"--must the emergency physician go farther?].

Ufer MR.

Unfallchirurgie. 1992 Apr;18(2):97-104. German.

PMID:
1580027

Supplemental Content

Support Center